Clinical leadership IceCure Medical has completed the ICE3 clinical trial—the largest controlled multi-location study for cryoablation in low-risk, early-stage breast cancer—demonstrating strong clinical validation and a compelling case for adoption by hospitals and cancer centers seeking non-surgical options.

US expansion Significant recent activity includes expansion of U.S. sales and marketing teams and the launch of a first U.S. clinical site network in collaboration with West Cancer Center, signaling growing demand and a ramp in in-market engagement with physicians and procurement teams.

In-office viability ProSense cryoablation uses liquid nitrogen to create large lethal zones with minimal safety burdens, enabling in-office procedures and reducing need for specialized cryogenic infrastructure—a strong value proposition for outpatient clinics and ambulatory surgery centers.

Global partnerships Strategic distributor relationships and regional partnerships (e.g., KTR Medical in Brazil) are accelerating international reach and education at major oncology congresses, presenting cross-border selling opportunities and channel-driven growth in diverse markets.

Financial and credibility signals With a revenue range of 1–10 million, substantial funding of 79 million, and FDA clearance plus CE marking, IceCure offers a credible investment profile for hospital procurement teams and potential channel partners seeking validated, scalable cryoablation solutions.